Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group

Simple item page
dc.coverageDOI: 10.1016/j.aohep.2025.101903
dc.creatorDiaz, Luis Antonio
dc.creatorArab, Juan Pablo
dc.creatorIdalsoaga, Francisco
dc.creatorPerelli, Javiera
dc.creatorVega, Javier
dc.creatorDirchwolf, Melisa
dc.creatorCarreño, Javiera
dc.creatorSamith, Bárbara
dc.creatorValério, Cynthia
dc.creatorMoreira, Rodrigo Oliveira
dc.creatorAcevedo, Mónica
dc.creatorBrahm, Javier
dc.creatorHernández, Nelia
dc.creatorGadano, Adrian
dc.creatorOliveira, Claudia P.
dc.creatorArrese, Marco
dc.creatorCastro-Narro, Graciela
dc.creatorPessoa, Mario G.
dc.date2025
dc.date.accessioned2025-11-18T19:46:09Z
dc.date.available2025-11-18T19:46:09Z
dc.description<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease globally. Based on the 2023 definition, MASLD is characterized by the presence of metabolic dysfunction and limited alcohol consumption (&lt;140 grams/week for women, &lt;210 grams/week for men). Given the significant burden of MASLD in Latin America, this guidance was developed by the Latin American Association for the Study of the Liver (ALEH) Working Group to address key aspects of its clinical assessment and therapeutic strategies. In Latin America, ultrasonography is recommended as the initial screening tool for hepatic steatosis due to its accessibility, while Fibrosis-4 (FIB-4) is preferred for fibrosis risk stratification, with further evaluation using more specific techniques (i.e., vibration-controlled transient elastography or Enhanced Liver Fibrosis [ELF] test). A Mediterranean diet is advised for all MASLD patients, with a target of 7–10% weight loss for those with excess weight. Complete alcohol abstinence is recommended for patients with significant fibrosis, and smoking cessation is encouraged regardless of fibrosis stage. Pharmacological options should be tailored based on the presence of steatohepatitis, liver fibrosis, excess weight, and diabetes, including resmetirom, incretin-based therapies, pioglitazone, and sodium-glucose cotransporter-2 inhibitors. Bariatric surgery may be considered for MASLD patients with obesity unresponsive to lifestyle and medical interventions. Hepatocellular carcinoma screening is advised for all cirrhotic patients, with consideration given to those with advanced fibrosis based on individual risk. Finally, routine cardiovascular risk assessment and proper diabetes prevention and management remain crucial for all patients with MASLD.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/58e89f54-f32e-41e4-a43c-c966098fca6c
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/54356
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.30 (2025) date: 2025-07-01 nr.2
dc.subjectCirrhosis
dc.subjectMAFLD
dc.subjectMASLD
dc.subjectNAFLD
dc.subjectNon-alcoholic cirrhosis
dc.subjectNon-alcoholic fatty liver disease
dc.subjectNoninvasive tests
dc.subjectScreening
dc.subjectSteatohepatitis
dc.subjectSteatosis
dc.subjectSteatotic liver disease
dc.subjectSDG 3 - Good Health and Well-being
dc.titleUpdated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working groupeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE